Based on the remarkable activity of ICIs in angiosarcoma patients, we performed exploratory analysis of immune and genetic features of patient 3 who achieved CR on a Phase I clinical trial of anti-CTLA4 antibody AGEN1884 (NCT02694822) (Fig. 2). Here, CTLA4 is linked to angiosarcoma.